- Home
- Products
- Customized ADCs
- HIV-1
- Anti-HIV-1 (Suvizumab)-MC-MMAF ADC
Anti-HIV-1 (Suvizumab)-MC-MMAF ADC (CAT#: ADC-W-2110)
This ADC product is comprised of an anti-HIV-1 monoclonal antibody conjugated via a MC linker to MMAF. The MMAF is targeted to certain cancers by immunerecognition and delivered into cancer cells via receptor mediated endocytosis. Within the cell, MMAF binds to tubulins, interrupts microtubule dynamics, and subsequently, induces cell death.
- ADC Target
- ADC Antibody
- ADC Linker
- ADC payload drug
- Name
- HIV-1
- Alternative Names
- HIV-1
- Overview
- HIV is a highly variable virus which mutates very readily. This means there are many different strains of HIV, even within the body of a single infected person. The strains of HIV1 can be classified into three groups : the "major" group M, the "outlier" group O and the "new" group N. These three groups may represent three separate introductions of simian immunodeficiency virus into humans. Group O appears to be restricted to West-Central Africa and group N, discovered in 1998 in Cameroon, is extremely rare. More than 90% of HIV1 infections belong to HIV1 group M.
- Overview
- Humanized Anti-HIV-1 IgG1-kappa antibody, Suvizumab
- Generic name
- Suvizumab
- Name
- MC (maleimidocaproyl)
- Description
- Noncleavable linkers, is considered noncleavable-meaning linker cleavage, and payload release does not depend on the differential properties between the plasma and some cytoplasmic compartments. Instead, the release of the cytotoxic drug is postulated to occur after internalization of the ADC via antigen-mediated endocytosis and delivery to lysosomal compartment, where the antibody is degraded to the level of amino acids through intracellular proteolytic degradation.
- Name
- MMAF
- Description
- Derived from Auristatin,are water-soluble dolastatin analogs of dolastatin 10. Dolastatin 10 belongs to dolastatin family and it can powerfully bind to tubulin, thus inhibiting polymerization mediated through the binding to the vinca alkaloid binding domain, and causes cell to accumulate in metaphase arrest.
For Research Use Only. NOT FOR CLINICAL USE.
Related Products
- Anti-ERBB2 (Trastuzumab)-SPDP-KG6E-AF ADC (CAT#: ADC-W-407)
- Anti-APP (Ponezumab)-MC-Vc-PAB-DMEA-(PEG2)-duocarmycin SA ADC (CAT#: ADC-W-715)
- Anti-TNFRSF10B (hTRA-8)-VC-MMAF ADC (CAT#: ADC-W-388)
- Anti-PCSK9 (Lodelcizumab)-SMCC-DM1 ADC (CAT#: ADC-W-1688)
- Anti-MS4A1 (Ocaratuzumab)-MC-MMAF ADC (CAT#: ADC-W-1564)
- Anti-ITGAV+ITGB3 (Etaracizumab)-MC-Vc-PAB-MMAE ADC (CAT#: ADC-W-2129)
- Anti-MIF (Imalumab)-MC-Vc-PAB-DMEA-(PEG2)-duocarmycin SA ADC (CAT#: ADC-W-2257)
- Anti-HBV surface antigen (Libivirumab)-SMCC-DM1 ADC (CAT#: ADC-W-1970)
- Anti-IL17A (Secukinumab)-SPDB-DM4 ADC (CAT#: ADC-W-1311)
- Anti-CD70 (clone h1F6 )-Mc-VC-PABC-MMAE ADC (CAT#: ADC-W-587)
Published Data
+ Submit Publications
Scientific Resources
Customer Reviews and FAQs
There are currently no Customer reviews or questions for ADC-W-2110. Click the button above to contact us or submit your feedback about this product.
Quick Links
Other Products
Same Target
Same Linker
Same Payload
| CAT# | Product Name | Linker | Payload |
| ADC-W-2112 | Anti-HIV-1 (Suvizumab)-MC-Vc-PAB-SN38 ADC | MC-Vc-PAB (maleimidocaproyl-valine-citrulline-p-aminobenzoyloxycarbonyl) | SN-38 (7-ethyl-10-hydroxycamptothecin) |
| ADC-W-2111 | Anti-HIV-1 (Suvizumab)-MC-Vc-PAB-MMAE ADC | MC-Vc-PAB (maleimidocaproyl-valine-citrulline-p-aminobenzoyloxycarbonyl) | MMAE |
| ADC-W-2108 | Anti-HIV-1 (Suvizumab)-SMCC-DM1 ADC | SMCC (N-succinimidyl 4-(Nmaleimidomethyl)cyclohexane-1-carboxylate) | DM1 (N2'-Deacetyl-N2'-(3-mercapto-1-oxopropyl)maytansine) |
| ADC-W-2109 | Anti-HIV-1 (Suvizumab)-SPDB-DM4 ADC | SPDB (N-succinimidyl-4-(2-pyridyldithio)butyrate) | DM4 (N2'-Deacetyl-N2'-(4-mercapto-4-methyl-1-oxopentyl)maytansine) |
| ADC-W-2113 | Anti-HIV-1 (Suvizumab)-MC-Vc-PAB-DMEA-(PEG2)-duocarmycin SA ADC | MC-Vc-PAB-DMEA-(PEG2) | duocarmycin SA |
| CAT# | Product Name | Linker | Payload |
| ADC-W-2612 | Anti-MS4A1 (Rituximab)-MC-MMAF ADC | MC (maleimidocaproyl) | MMAF |
| ADC-W-493 | Anti-CD19 (clone huB4)-Mc-MMAF ADC | Mc (maleimidocaproyl) | MMAF (Monomethyl auristatin F) |
| ADC-W-491 | Anti-TNFRSF17-Mc-MMAF ADC | Mc (maleimidocaproyl) | MMAF (Monomethyl auristatin F) |
| ADC-W-452 | Anti-CD70 (clone 1F6)-Mc-MMAF ADC | Mc (maleimidocaproyl) | MMAF (Monomethyl auristatin F) |
| ADC-W-2622 | Anti-NCAM1 (Lorvotuzumab )-MC-MMAF ADC | MC (maleimidocaproyl) | MMAF |
| CAT# | Product Name | Linker | Payload |
| ADC-W-2567 | Anti-MUC16 (Sofituzumab)-MC-MMAF ADC | MC (maleimidocaproyl) | MMAF |
| ADC-W-2561 | Anti-MSLN (Anetumab )-MC-MMAF ADC | MC (maleimidocaproyl) | MMAF |
| ADC-W-2544 | Anti-CD44 (Bivatuzumab)-MC-MMAF ADC | MC (maleimidocaproyl) | MMAF |
| ADC-W-2556 | Anti-CD79B (Polatuzumab )-MC-MMAF ADC | MC (maleimidocaproyl) | MMAF |
| ADC-W-2585 | Anti-EGFR (Zalutumumab)-MC-MMAF ADC | MC (maleimidocaproyl) | MMAF |
Online Inquiry
Welcome! For price inquiries, please feel free to contact us through the form on the left side. We will get back to you as soon as possible.
